REQUEST FOR CONSULTANT SERVICES PROPOSAL (RFP)
Pharmacokinetic (serum hormone levels) and pharmacodynamic (suppression of ovulation) evidence indicates that the 104 mg subcutaneous formulation of depot medroxyprogesterone acetate (DMPA-SC) provides contraceptive efficacy beyond three months. Extending the reinjection interval of DMPA-SC from 3 to 4 months would reduce long-term progestin exposure, potentially shorten the time to return to ovulation and fertility, and possibly reducing other dose-dependent side effects. Also, having one less injection each year would decrease programmatic costs and further facilitate access to DMPA-SC in resource-constrained settings.
With support from the Children’s Investment Fund Foundation (CIFF), FHI Partners is conducting several activities to establish the evidence base for and support the registration of a generic DMPA-SC as a 4-month product. The availability of such a product has the potential to improve consumer experience with a significantly lower dose, offer procurement savings that could grow to $10M per year, and alleviate supply chain bottlenecks faced with the current manufacture of Sayana® Press.
Understanding service delivery implications and user and provider preferences for and reactions to a 4-month product are key to the successful introduction of this new injectable. This scope of work (SOW) will support two research activities focused on market/service delivery implications (Activity 1) and user considerations (Activity 2) for the introduction of a 4-month DMPA-SC product in Nigeria.